Oncotarget

Reviews:

This article is currently under investigation. We strongly recommend that this article is not cited until the investigation is completed.

Concurrent neoadjuvant chemoradiotherapy could improve survival outcomes for patients with esophageal cancer: a meta-analysis based on random clinical trials

Baoxing Liu, Yacong Bo, Kunlun Wang, Yang Liu, Xiance Tang, Yan Zhao, Erjiang Zhao and Ling Yuan _

PDF  |  HTML  |  How to cite

Oncotarget. 2017; 8:20410-20417. https://doi.org/10.18632/oncotarget.14669

Metrics: PDF 2285 views  |   HTML 2715 views  |   ?  


Abstract

Baoxing Liu1,*, Yacong Bo2,*, Kunlun Wang1, Yang Liu1, Xiance Tang1, Yan Zhao1, Erjiang Zhao1 and Ling Yuan1

1 Affiliated Tumor Hospital of Zhengzhou University, Henan Tumor Hospital, Zhengzhou, Henan, China

2 Department of Nutrition and Food Hygiene, College of Public Health, Zhengzhou University, Affiliated Tumor Hospital of Zhengzhou University, Henan Tumor Hospital, Zhengzhou, China

* These authors have contributed equally to this work

Correspondence to:

Ling Yuan, email:

Keywords: neoadjuvant concurrent chemoradiotherapy; esophageal cancer; overall survival; R0 resection rate; progression-free survival

Received: October 05, 2016 Accepted: January 09, 2017 Published: January 15, 2017

Abstract

Background: The long-term survival benefit of concurrent neoadjuvant chemoradiotherapy in patients with resectable esophageal cancer remains controversial. In the present study, we conducted a meta-analysis to assess these effectiveness.

Methods: We searched for most relevant studies published up to the end of August 2016, using Pubmed and web of knowledge. And additional articles were identified from previous meta-analysis. The hazard ratio (HR, for overall survival and progression free survival) or risk ratio (RR, for R0 resection) with its corresponding 95 % confidence interval (CI) were used to assess the pooled effect.

Results: Twelve articles including 1756 patients were included in the meta-analysis. Concurrent neoadjuvant chemoradiotherapy followed by surgery was associated with significantly improved overall survival (HR=0.76 , 95% CI= 0.68-0.86), progression survival (HR =0.69, 95% CI= 0.59-0.81), and R0 resection rate(RR =1.17, 95% CI= 1.03-1.33). Subgroup analysis suggested that concurrent neoadjuvant chemoradiotherapy could improve overall survival outcome for squamous cell carcinoma (HR=0.73, 95%CI=0.61-0.88) but not those for adenocarcinoma (HR=0.72, 95%CI=0.48-1.04).

Conclusion: Our findings suggested that concurrent neoadjuvant chemoradiotherapy was associated with a significant survival benefit in patients with esophageal cancer.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 14669